Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa

References

• Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, Vignat J, Ferlay J, Bray F, Plummer M, et al. Global burden of human papillomavirus and related diseases. Vaccine 2012; 30 Suppl 5: F12-F23; PMID:23199955; http://dx.doi.org/10.1016/j.vaccine.2012.07.055
   PubMed Web of Science ®Google Scholar
• Koshiol JE, Laurent SA, Pimenta JM. Rate and predictors of new genital warts claims and genital warts-related healthcare utilization among privately insured patients in the United States. Sex Transm Dis 2004; 31:748-52; PMID:15608590; http://dx.doi.org/10.1097/01.olq.0000145851.76025.ad
   PubMed Web of Science ®Google Scholar
• Clifford GM, Smith JS, Plummer M, Münoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003; 88:63-73; PMID:12556961; http://dx.doi.org/10.1038/sj.bjc.6600688
   PubMed Web of Science ®Google Scholar
• Sitas F, Urban M, Stein L, Beral V, Ruff P, Hale M, Patel M, O'Connell D, Yu XQ, Verzijden A, et al. The relationship between anti-HPV-16 IgG seropositivity and cancer of the cervix, anogenital organs, oral cavity and pharynx, oesophagus and prostate in a black South African population. Infect Agent Cancer 2007; 2:6; PMID:17331260; http://dx.doi.org/10.1186/1750-9378-2-6
   PubMedGoogle Scholar
• Elit L, Voruganti S, Simunovic M. Invasive vulvar cancer in a woman with human immunodeficiency virus: case report and review of the literature. Gynecol Oncol 2005; 98:151-4; PMID:15922443; http://dx.doi.org/10.1016/j.ygyno.2005.03.039
   PubMedGoogle Scholar
• Banura C, Franceschi S, Doorn LJ, Arslan A, Wabwire-Mangen F, Mbidde EK, Quint W, Weiderpass E. Infection with human papillomavirus and HIV among young women in Kampala, Uganda. J Infect Dis 2008; 197:555-62; PMID:18237268; http://dx.doi.org/10.1086/526792
   PubMed Web of Science ®Google Scholar
• Johnson JE, Dehaeck CM, Soeters R, Williamson AL. Typing and molecular characterization of human papillomaviruses in genital warts from South African women. J Med Virol 1991; 33:39-42; PMID:1849982; http://dx.doi.org/10.1002/jmv.1890330108
   PubMedGoogle Scholar
• De Vuyst H, Alemany L, Lacey C, Chibwesha CJ, Sahasrabuddhe V, Banura C, Denny L, Parham GP. The burden of human papillomavirus infections and related diseases in sub-saharan Africa. Vaccine 2013; 31 Suppl 5: F32-F46; PMID:24331746; http://dx.doi.org/10.1016/j.vaccine.2012.07.092
   PubMed Web of Science ®Google Scholar
• Denny L, Adewole I, Anorlu R, Dreyer G, Moodley M, Smith T, Snyman L, Wiredu E, Molijn A, Quint W, et al. Human papillomavirus prevalence and type distribution in invasive cervical cancer in sub-Saharan Africa. Int J Cancer 2014; 134:1389-98; PMID:23929250; http://dx.doi.org/10.1002/ijc.28425
   PubMed Web of Science ®Google Scholar
• Anorlu RI. Cervical cancer: the sub-Saharan African perspective. Reprod Health Matters 2008; 16:41-9; PMID:19027621; http://dx.doi.org/10.1016/S0968-8080(08)32415-X
   PubMed Web of Science ®Google Scholar
• Barr E, Sings HL. Prophylactic HPV vaccines: new interventions for cancer control. Vaccine 2008; 26:6244-57; PMID:18694795; http://dx.doi.org/10.1016/j.vaccine.2008.07.056
   PubMed Web of Science ®Google Scholar
• Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GWK, Ferris DG, Steben M, Bryan JT, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356:1928-43; PMID:17494926; http://dx.doi.org/10.1056/NEJMoa061760
   PubMed Web of Science ®Google Scholar
• FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356:1915-27; PMID:17494925; http://dx.doi.org/10.1056/NEJMoa061741
   PubMed Web of Science ®Google Scholar
• Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, Castellsague X, Rusche SA, Lukac S, Bryan JT, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006; 118:2135-45; PMID:17079588; http://dx.doi.org/10.1542/peds.2006-0461
   PubMed Web of Science ®Google Scholar
• Reisinger KS, Block SL, Lazcano-Ponce E, Samakoses R, Esser MT, Erick J, Puchalski D, Giacoletti KED, Sings HL, Lukac S, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Ped Infect Dis Journal 2007; 26:201-9; PMID:17484215; http://dx.doi.org/10.1097/01.inf.0000253970.29190.5a
   PubMed Web of Science ®Google Scholar
• Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Jr., Penny ME, Aranda C, Vardas E, Moi H, Jessen H, Hillman R, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011; 364:401-11; PMID:21288094; http://dx.doi.org/10.1056/NEJMoa0909537
   PubMed Web of Science ®Google Scholar
• Palefsky JM, Giuliano AR, Goldstone S, Moreira ED, Aranda C, Jessen H, Hillman R, Ferris D, Coutlee F, Stoler MH, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. New Engl J of Med 2011; 365:1576-85; PMID:22029979; http://dx.doi.org/10.1056/NEJMoa1010971
   PubMed Web of Science ®Google Scholar
• Tay EH, Garland S, Tang G, Nolan T, Huang LM, Orloski L, Lu S, Barr E. Clinical trial experience with prophylactic HPV 6/11/16/18 VLP vaccine in young women from the Asia-Pacific region. Int J Gynaecol Obstet 2008; 102:275-83; PMID:18555997; http://dx.doi.org/10.1016/j.ijgo.2008.03.021
   PubMedGoogle Scholar
• Kang S, Kim KH, Kim YT, Kim YT, Kim JH, Song YS, Shin SH, Ryu HS, Han JW, Kang JH, et al. Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, placebo-controlled trial in 176 Korean subjects. Int J Gynecol Cancer 2008; 18:1013-9; PMID:17986242; http://dx.doi.org/10.1111/j.1525-1438.2007.01123.x
   PubMed Web of Science ®Google Scholar
• Perez G, Lazcano-Ponce E, Hernandez-Avila M, Garcia PJ, Munoz N, Villa LL, Bryan J, Taddeo FJ, Lu S, Esser MT, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women. Int J Cancer 2008; 122:1311-8; PMID:18000825; http://dx.doi.org/10.1002/ijc.23260
   PubMed Web of Science ®Google Scholar
• Lazcano-Ponce E, Perez G, Cruz-Valdez A, Zamilpa L, Aranda-Flores C, Hernandez-Nevarez P, Viramontes JL, Salgado-Hernandez J, James M, Lu S, et al. Impact of a quadrivalent HPV6/11/16/18 vaccine in Mexican women: public health implications for the region. Arch Med Res 2009; 40:514-24; PMID:19853193; http://dx.doi.org/10.1016/j.arcmed.2009.07.008
   PubMedGoogle Scholar
• Majewski S, Bosch FX, Dillner J, Iversen OE, Kjaer SK, Munoz N, Olsson SE, Paavonen J, Sigurdsson K, Bryan J, et al. The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus-like particle vaccine in European women aged 16 to 24. J Eur Acad Dermatol Venereol 2009; 23:1147-55; PMID:19453788; http://dx.doi.org/10.1111/j.1468-3083.2009.03266.x
   PubMed Web of Science ®Google Scholar
• Li R, Li Y, Radley D, Liu Y, Huang T, Sings HL, Zhang L, Wang W, Zhong X, Saah AJ. Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, double-blind, placebo-controlled trial in Chinese males and females. Vaccine 2012; 30:4284-91; PMID:22433961; http://dx.doi.org/10.1016/j.vaccine.2012.02.079
   PubMed Web of Science ®Google Scholar
• Giuliano A, Lazcano-Ponce E, Villa L, Nolan T, Marchant CD, Radley D, Golm G, McCarroll K, Yu J, Esser M, et al. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine. J Infect Dis 2007; 196:1153-62. © 2007 by the Infectious Diseases Society of America; PMID:17955433; http://dx.doi.org/10.1086/521679
   PubMedGoogle Scholar
• Villa LL, Costa RLR, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6:271-8; PMID:15863374; http://dx.doi.org/10.1016/S1470-2045(05)70101-7
   PubMed Web of Science ®Google Scholar
• Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985; 4:213-26; PMID:4023479; http://dx.doi.org/10.1002/sim.4780040211
   PubMed Web of Science ®Google Scholar
• International patent numbers WO 2003/019143 A2, WO 2006/116276 A2, and WO 2006/116303 A2. Available at http://www.wipo.int/portal/index.html.en.Accessed 2/21/2011. 2008
   Google Scholar
• Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, Alvarez FB, Bautista OM, Jansen KU, Barr E. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006; 107:18-27; PMID:16394035; http://dx.doi.org/10.1097/01.AOG.0000192397.41191.fb
   PubMed Web of Science ®Google Scholar
• Opalka D, Lachman CE, MacMullen SA, Jansen KU, Smith JF, Chirmule N, Esser MT. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16 and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 2003; 10:108-15; PMID:12522048
   PubMedGoogle Scholar
• Dias D, Van Doren J, Schlottmann S, Kelly S, Puchalski D, Ruiz W, Boerckel P, Kessler J, Antonello JM, Green T, et al. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomavirus 6, 11, 16 and 18. Clin Diagn Lab Immunol 2005; 12:959-69; PMID:16085914
   PubMedGoogle Scholar
• Clark LR, Myers ER, Huh W, Joura EA, Paavonen J, Perez G, James MK, Sings HL, Haupt RM, Saah AJ, et al. Clinical trial experience with prophylactic human papillomavirus 6/11/16/18 vaccine in young black women. J Adolesc Health 2013; 52:322-9; PMID:23299013; http://dx.doi.org/10.1016/j.jadohealth.2012.07.003
   PubMed Web of Science ®Google Scholar
• Block SL, Brown DR, Chatterjee A, Gold MA, Sings HL, Meibohm A, Dana A, Haupt RM, Barr E, Tamms GM, et al. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine. Pediatr Infect Dis J 2009; 29:95-101; PMID:19952863; http://dx.doi.org/10.1097/INF.0b013e3181b77906
   PubMed Web of Science ®Google Scholar
• Center for Disease Control and Prevention. New study shows HPV vaccine helping lower HPV infection rates in teen girls. Available at: http://www.cdc.gov/media/releases/2013/p0619-hpv-vaccinations.html . 2014
   Google Scholar
• Markowitz LE, Hariri S, Lin C, Dunne EF, Steinau M, McQuillan G, Unger ER. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis 2013; 208:385-93; PMID:23785124; http://dx.doi.org/10.1093/infdis/jit192
   PubMed Web of Science ®Google Scholar
• Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Cummins E, Liu B, Bateson D, McNamee K, Garefalakis M, Garland SM. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 2012; 206:1645-51; PMID:23087430; http://dx.doi.org/10.1093/infdis/jis590
   PubMed Web of Science ®Google Scholar
• Brotherton J, Fridman M, Saville M, Gertig D. First indication of a possible impact on cervical abnormalities following a national HPV vaccination program in Victoria, Australia. Available at: http://hpv2010.org/mwg-internal/de5fs23hu73ds/progress?id=RKGuErfdN1. 2010; Montreal Canada
   Google Scholar
• Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011; 377:2085-92; PMID:21684381; http://dx.doi.org/10.1016/S0140-6736(11)60551-5
   PubMed Web of Science ®Google Scholar
• Powell SE, Hariri S, Steinau M, Bauer HM, Bennett NM, Bloch KC, Niccolai LM, Schafer S, Unger ER, Markowitz LE. Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions. Vaccine 2012; 31:109-13; PMID:23137842; http://dx.doi.org/10.1016/j.vaccine.2012.10.092
   PubMed Web of Science ®Google Scholar
• Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med 2013; 11:227; PMID:24148310; http://dx.doi.org/10.1186/1741-7015-11-227
   PubMed Web of Science ®Google Scholar
• Ali H, Donovan B, Wand H, Read TR, Regan DG, Grulich AE, Fairley CK, Guy RJ. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 2013; 346:f2032; PMID:23599298; http://dx.doi.org/10.1136/bmj.f2032
   PubMed Web of Science ®Google Scholar
• Ali H, Guy RJ, Wand H, Read TR, Regan DG, Grulich AE, Fairley CK, Donovan B. Decline in in-patient treatments of genital warts among young Australians following the national HPV vaccination program. BMC Infect Dis 2013; 13:140; PMID:23506489; http://dx.doi.org/10.1186/1471-2334-13-140
   PubMed Web of Science ®Google Scholar
• Read TR, Hocking JS, Chen MY, Donovan B, Bradshaw CS, Fairley CK. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2011; 87:544-7; PMID:21970896; http://dx.doi.org/10.1136/sextrans-2011-050234
   PubMed Web of Science ®Google Scholar
• Bauer HM, Wright G, Chow J. Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007-2010. Am J Public Health 2012; 102:833-5; PMID:22420808; http://dx.doi.org/10.2105/AJPH.2011.300465
   PubMed Web of Science ®Google Scholar
• Nsouli-Maktabi H, Ludwig SL, Yerubandi UD, Gaydos JC. Incidence of genital warts among U.S. service members before and after the introduction of the quadrivalent human papillomavirus vaccine. MSMR 2013; 20:17-20; PMID:23461306
   PubMedGoogle Scholar
• Leval A, Herweijer E, Arnheim-Dahlstrom L, Walum H, Frans E, Sparen P, Simard JF. Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. J Infect Dis 2012; 206:860-6; PMID:22815381; http://dx.doi.org/10.1093/infdis/jis405
   PubMed Web of Science ®Google Scholar
• Baandrup L, Blomberg M, Dehlendorff C, Sand C, Andersen KK, Kjaer SK. Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. Sex Transm Dis 2013; 40:130-5; PMID:23324976
   PubMed Web of Science ®Google Scholar
• Mikolajczyk RT, Kraut AA, Horn J, Schulze-Rath R, Garbe E. Changes in incidence of anogenital warts diagnoses after the introduction of human papillomavirus vaccination in Germany-an ecologic study. Sex Transm Dis 2013; 40:28-31; PMID:23250300; http://dx.doi.org/10.1097/OLQ.0b013e3182756efd
   PubMed Web of Science ®Google Scholar
• Blomberg M, Dehlendorff C, Munk C, Kjaer SK. Strongly decreased risk of genital warts after vaccination against human papillomavirus: nationwide follow-up of vaccinated and unvaccinated girls in Denmark. Clin Infect Dis 2013; 57:929-34; PMID:23804192; http://dx.doi.org/10.1093/cid/cit436
   PubMed Web of Science ®Google Scholar
• Delere Y, Remschmidt C, Leuschner J, Schuster M, Fesenfeld M, Schneider A, Wichmann O, Kaufmann AM. Human papillomavirus prevalence and probable first effects of vaccination in 20 to 25 year-old women in Germany: a population-based cross-sectional study via home-based self-sampling. BMC Infect Dis 2014; 14:87; PMID:24552260; http://dx.doi.org/10.1186/1471-2334-14-87
   PubMed Web of Science ®Google Scholar
• Baldur-Felskov B, Dehlendorff C, Munk C, Kjaer SK. Early impact of human papillomavirus vaccination on cervical neoplasia–nationwide follow-up of young Danish women. J Natl Cancer Inst 2014; 106:djt460; PMID:24552678; http://dx.doi.org/10.1093/jnci/djt460
   PubMed Web of Science ®Google Scholar
• Binagwaho A, Wagner CM, Gatera M, Karema C, Nutt CT, Ngabo F. Achieving high coverage in Rwanda's national human papillomavirus vaccination programme. Bull World Health Organ 2012; 90:623-8; PMID:22893746; http://dx.doi.org/10.2471/BLT.11.097253
   PubMed Web of Science ®Google Scholar
• Moodley J, Kawonga M, Bradley J, Hoffman M. Challenges in implementing a cervical screening program in South Africa. Cancer Detect Prev 2006; 30:361-8; PMID:16963193; http://dx.doi.org/10.1016/j.cdp.2006.07.005
   PubMedGoogle Scholar
• Hoque M, Hoque E, Kader SB. Evaluation of cervical cancer screening program at a rural community of South Africa. East Afr J Public Health 2008; 5:111-6; PMID:19024420
   PubMedGoogle Scholar
• Mvundura M, Tsu V. Estimating the costs of cervical cancer screening in high-burden Sub-Saharan African countries. Int J Gynaecol Obstet 2014; 126:151-5; PMID:24792401; http://dx.doi.org/10.1016/j.ijgo.2014.02.012
   PubMed Web of Science ®Google Scholar
• Awolude OA, Morhason-Bello IO, Denny LA, Adewole IF. Human papillomavirus infection and related cancers in sub-Saharan Africa: burden and tools for prevention. Vaccine 2013; 31 Suppl 5: vii-vix; PMID:24331751
   PubMedGoogle Scholar